SciSparc

What SciSparc does

SciSparc Ltd. is an Israeli clinical-stage pharmaceutical company (NASDAQ: SPRC; headquartered in Giv'atayim) developing proprietary cannabinoid-based drug candidates for neurological and pain indications. Its lead platforms, SCI-110 (Dronabinol combined with the proprietary CannAmide PEA formulation) and SCI-210 (CBD combined with CannAmide), are in clinical trials for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's-related agitation, and Autism Spectrum Disorder; SCI-160, a synthetic CB2 receptor agonist (HU-433) synthesized by Prof. Raphael Mechoulam, is in pre-clinical pain studies. SciSparc also markets CannAmide as a Health Canada–licensed nutraceutical (400mg tablets) and, via 2025–2026 acquisitions, has expanded into medical devices (MUSE endoscopic GERD system, acquired from Xylo Technologies) and quantum-simulation software for clinical-trial analytics (CliniQuantum, acquired indirectly through NeuroThera Labs).

Revenue is essentially pre-commercial: drug candidates are not FDA-approved, CannAmide is the only commercial product with limited Canadian nutraceutical sales, and the MUSE device is pre-launch. Value-creation mechanics depend on FDA/regulatory milestones, partnership/licensing deals, or future device commercialization in North America, Europe, and Latin America. The corporate structure is complex following the October 2025 transfer of the pharmaceutical portfolio into a controlling ~75% stake in NeuroThera Labs Inc. (TSXV-listed, formerly Miza III Ventures), with NeuroThera subsequently acquiring ~54% of CliniQuantum in 2026. The company divested MitoCareX (cancer therapeutics) to N2OFF for US$700,000 plus equity, executed two 1-for-9 reverse stock splits (2025 and 2026), and reported negative stockholders' equity of ~US$81,000 as of June 30, 2025, triggering a Nasdaq listing non-compliance notice. Operations are supported by a 1–10 employee base, cumulative disclosed equity raises of ~US$16.3 million (2022–2023), and leadership under Chairman Itschak Shrem, CEO/CFO Oz Adler, President Amitay Weiss, and CTO Dr. Adi Zuloff-Shani.

Name

SciSparc

Legal name

SciSparc Ltd.

Website

https://investor.scisparc.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

SciSparc Ltd. is an Israeli clinical-stage pharmaceutical company (NASDAQ: SPRC) developing cannabinoid-based drug candidates — SCI-110, SCI-210, and SCI-160 — for neurological, autism, and pain indications, with CannAmide nutraceutical sales in Canada and recent expansion into MUSE GERD devices and CliniQuantum quantum-simulation software via its NeuroThera Labs subsidiary.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Cannabinoid pharmaceuticals
• Clinical drug development
• Neurological disorder treatments
• Pain management therapies
• Nutraceutical supplements

Headquarters

HQ city

Giv'atayim

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Development: SciSparc develops proprietary cannabinoid-based drug candidates through clinical trials. Revenue will come from drug approvals and commercialization, with potential for partnership or licensing deals.
2. Nutraceutical Products: CannAmide product sold as a supplement in the nutraceuticals market with Health Canada product license.
3. Medical Device Commercialization: Commercialization of MUSE endoscopic system for GERD treatment targeting North America, Europe, and Latin America markets.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

SciSparc is a clinical-stage pharmaceutical company developing proprietary cannabinoid-based drug candidates (SCI-110, SCI-210, SCI-160) targeting neurological disorders (Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's, Autism) and chronic pain. The company also sells CannAmide, a 400mg PEA oral supplement, in Canada's nutraceutical market under Health Canada license. Through acquisitions, SciSparc has expanded into medical devices (MUSE endoscopic system for GERD) and quantum simulation platforms for clinical trial analysis.

Product overview

SciSparc is a clinical-stage pharmaceutical company developing proprietary drug candidates targeting neurological and pain conditions. The company operates two main proprietary drug platforms: SCI-110 combines Dronabinol (FDA-approved THC) with the proprietary CannAmide formulation for CNS disorders including Tourette Syndrome and Alzheimer's; SCI-210 combines CBD with CannAmide for Autism Spectrum Disorder and Status Epilepticus. The company also develops SCI-160, a synthetic CB2 receptor agonist for pain treatment. Beyond pharmaceuticals, SciSparc offers CannAmide as a nutraceutical product (400mg tablets) through its subsidiary SciSparc Nutraceuticals, and has expanded into medical devices through acquisition of the MUSE endoscopic system for GERD treatment.

Differentiator

Problem solved

Functional benefit

Brands

• CannAmide: Proprietary palmitoylethanolamide (PEA) oral formulation for reduction of chronic pain and inflammation. Available in tablet form with 400mg active pharmaceutical ingredient. Designated product license from Health Canada for sale as supplement.

Products and services

• SCI-110

Quantifiable outcome

• Targeting Tourette syndrome market projected to reach $3.38 billion by 2030
• +1 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Clearmind Medicine Inc.coreStrategic or Co-development Partner · 10 March 2026Collaboration with Clearmind Medicine on combination therapies using MEAI (Clearmind's proprietary 5-methoxy-2-aminoindane) with PEA (NeuroThera's proprietary CannAmide). Joint development of therapies for depression, binge behavior disorders, obesity, and fatty liver disease. Includes international patent applications and ongoing clinical development.
• CliniQuantum Ltd.coreStrategic or Co-development Partner · 10 March 2026NeuroThera Labs (75% owned by SciSparc) acquired approximately 54% interest in CliniQuantum, an Israeli technology company developing quantum simulation platform for clinical trial data analysis. Deal valued at approximately $9.46 million through share issuance. Includes earn-out payments up to $2.5 million tied to patent and fundraising milestones over three years.
• Xylo Technologies Ltd.coreOEM/ Whitelabel/ Licensing Partner · 26 November 2025Acquisition of MUSE system IP portfolio including patents, trademarks, and intellectual property rights for endoscopic systems and medical cameras. SciSparc issued shares representing 19.99% of outstanding share capital as consideration. Enables entry into GERD device market.
• NeuroThera Labs Inc.coreStrategic or Co-development Partner · 24 October 2025SciSparc acquired controlling interest of approximately 75% in NeuroThera Labs (formerly Miza III Ventures Inc.), a publicly traded company on TSX Venture Exchange in Canada. SciSparc transferred its clinical-stage pharmaceutical portfolio and 51% equity in SciSparc Nutraceuticals to NeuroThera. Deal valued at approximately $11.6 million. SciSparc received 63.3 million shares, 4 million warrants, and up to 48 million contingent rights.
• N2OFF Inc.minorStrategic or Co-development Partner · 20 October 2025Sale of majority-owned subsidiary MitoCareX to N2OFF for $700,000 and 40% equity stake. MitoCareX focused on cancer therapeutics using computational platform and molecular screening systems. Transaction closed October 20, 2025.
• Miza III Ventures Inc.coreStrategic or Co-development Partner · 9 October 2025SciSparc agreed to acquire controlling stake by transferring pharmaceutical assets and 51% equity stake for approximately $11.6 million. Deal finalized around October 22, 2025 with Miza rebranding as NeuroThera Labs Inc.
• Quantum X Labs Ltd.coreOEM/ Whitelabel/ Licensing PartnerCliniQuantum holds exclusive worldwide license agreement with Quantum X Labs Ltd. for patented quantum Monte Carlo methods for identifying patient subpopulations in clinical trials, sourced from Ramot at Tel Aviv University.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Corbus Pharmaceuticals: Clinical-stage pharmaceutical company developing cannabinoid-derived therapeutics, including CB2-targeting candidates. Closely comparable to SciSparc's SCI-110 and SCI-160 programs in mechanism and stage.
• Zynerba Pharmaceuticals: Develops transdermal cannabinoid therapies for CNS indications including Fragile X syndrome and autism spectrum disorder — directly comparable to SciSparc's SCI-210 Autism Spectrum Disorder program.
• Anavex Life Sciences: Clinical-stage CNS specialty pharma developing therapies for Alzheimer's disease, Rett syndrome, and Parkinson's — directly comparable to SciSparc's neurological and rare-disease CNS pipeline targeting similar indications.
• Marinus Pharmaceuticals: Specialty neurology pharmaceutical company developing ganaxolone for rare seizure disorders including CDKL5 deficiency disorder and Status Epilepticus — directly overlapping with SciSparc's SCI-210 Status Epilepticus program.
• EndoGastric Solutions: Commercial-stage medical device company developing the EsophyX endoscopic system for GERD treatment — directly comparable to SciSparc's MUSE system as a competing endoscopic GERD device in the same $3B+ market.
• Bionomics Limited: Clinical-stage CNS specialty pharmaceutical company developing therapies for anxiety, PTSD, and cognitive disorders — a comparable size, stage, and CNS specialty focus to SciSparc's clinical pipeline.

Broad incumbents

• Jazz Pharmaceuticals (GW Pharmaceuticals legacy): Markets Epidiolex, the first FDA-approved CBD drug for epilepsy, and acquired GW Pharmaceuticals. Represents the most established large-cap analog in cannabinoid-based neurology therapeutics, validating the regulatory pathway SciSparc is pursuing.
• Axsome Therapeutics: Commercial-stage CNS specialty pharma with FDA-approved therapies for migraine and depression — a relevant benchmark for SciSparc's CNS specialty strategy and an example of a successful clinical-to-commercial transition in this category.

Emerging players

• Mind Medicine (MindMed): Clinical-stage psychedelic- and cannabinoid-inspired therapeutics company targeting CNS conditions including anxiety and ADHD. Comparable to SciSparc's cannabinoid-based CNS approach but with overlapping psychedelic adjacency.
• Clearmind Medicine: Clinical-stage psychedelic-derived pharmaceutical company and SciSparc's active co-development partner on MEAI+PEA combination therapies for depression, binge behavior, obesity, and MASLD. Strong strategic and mechanistic overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/therapix-biosciences-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SciSparc